Irinotecan liposomal (CSPC)

伊立替康脂质体 (石药集团)

Report date: 2026/05/12 20:00:17

Base Information

Drug NameIrinotecan liposomal (CSPC)
Drug Alias NameCPO120
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSmall Cell Lung CarcinomaPancreatic NeoplasmsBile Duct Neoplasms +[4] 
Global Approved IndicationsPancreatic Neoplasms
Approved Indications in ChinaPancreatic Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/09/12
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdCspc Ouyi Pharmaceutical Co LtdConjupro Bioerapecitics Inc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaPancreatic NeoplasmsBreast Neoplasms
Inactive IndicationsBile Duct Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank